Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache SocietyAn extension phase of the DELIVER study with Vyepti® (eptinezumab) demonstrated long-lasting migraine preventive effects with treatment for up to 18 months, reducing both frequency and severity.
Rexulti is the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer s disease
Valby, Denmark, May 11, 2023 - H. Lundbeck A/S and. | May 11, 2023
Notice of Annual General Meeting pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Lundbeck welcomes acceptance of Vyepti s marketing authorization application by the European Medicines Agency for the prevention of migraine news.europawire.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news.europawire.eu Daily Mail and Mail on Sunday newspapers.